Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)-Reference-Cited by-同舟云学术

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

Published:2010-03 Issue:3 Volume:11 Page:266-274
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bartlett John MS,Munro Alison F,Dunn Janet A,McConkey Christopher,Jordan Sarah,Twelves Chris J,Cameron David A,Thomas Jeremy,Campbell Fiona M,Rea Daniel W,Provenzano Elena,Caldas Carlos,Pharoah Paul,Hiller Louise,Earl Helena,Poole Christopher J

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Molecular portraits of human breast tumours;Perou;Nature,2000

2. Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer;Spears;Biomarker Med,2008

3. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?;Tovey;Clin Cancer Res,2005

4. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy;Bartlett;J Clin Oncol,2007

5. Topoisomerase II alpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers;Miyoshi;Cancer Letts,2008

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B Breast Cancer: A Pilot Study;International Journal of Molecular Sciences;2024-04-19

2. Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies;Chromosome Research;2023-09-18

3. The progress in our understanding of CIN in breast cancer research;Frontiers in Oncology;2023-02-16

4. Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction;Proceedings of the National Academy of Sciences;2022-12-27

5. The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer;Histopathology;2022-08-08